- Home
- BTMD vs ACRV Comparison
BTMD vs ACRV Comparison
Compare BTMD & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTMD | ACRV |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.6M | 74.5M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | BTMD | ACRV |
|---|---|---|
| Price | $2.59 | $2.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.00 | ★ $14.67 |
| AVG Volume (30 Days) | 142.6K | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 270.48 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $195,645,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.85 | $805.34 |
| P/E Ratio | $3.29 | ★ N/A |
| Revenue Growth | ★ 1.34 | N/A |
| 52 Week Low | $2.32 | $1.05 |
| 52 Week High | $6.98 | $8.00 |
Technical Indicators
Market Signals| Indicator | BTMD | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 60.76 |
| Support Level | $2.32 | $2.22 |
| Resistance Level | $2.75 | $2.39 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 52.69 | 86.15 |
Price Performance
Historical ComparisonAbout BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.